A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer

Phase I ◽

Phase I Study ◽

Metastatic Cancer ◽

A phase I study of S-3304 a matrix metalloproteinase inhibitor in patients with solid tumors

European Journal of Cancer ◽

10.1016/s0959-8049(02)80895-4 ◽

2002 ◽

Vol 38 ◽

pp. S77

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566

Annals of Oncology ◽

10.1023/a:1011183905848 ◽

2001 ◽

Vol 12 (3) ◽

pp. 389-395 ◽

Cited By ~ 43

Author(s):

C. Erlichman ◽

A.A. Adjei ◽

S.R. Alberts ◽

J.A. Sloan ◽

R.M. Goldberg ◽

...

Keyword(s):

Phase I ◽

Phase I Study ◽

The Matrix

A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-06-1586 ◽

2007 ◽

Vol 13 (7) ◽

pp. 2091-2099 ◽

Cited By ~ 30

Author(s):

Alberto A. Chiappori ◽

S. Gail Eckhardt ◽

Ronald Bukowski ◽

Daniel M. Sullivan ◽

Minoru Ikeda ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Pharmacodynamic Study

Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer

Investigational New Drugs ◽

10.1007/bf00210790 ◽

1996 ◽

Vol 14 (2) ◽

Cited By ~ 61

Author(s):

Slawomir Wojtowicz-Praga ◽

Jennifer Low ◽

John Marshall ◽

Elizabeth Ness ◽

Robert Dickson ◽

...

Keyword(s):

Phase I ◽

Advanced Cancer ◽

Phase I Trial ◽

A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-004-0905-z ◽

2004 ◽

Vol 55 (2) ◽

pp. 136-142 ◽

Cited By ~ 5

Author(s):

André Planting ◽

Ate van der Gaast ◽

Patrick Schöffski ◽

Michele Bartkowski ◽

Coleta Verheij ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Advanced Solid Tumors ◽

The Matrix ◽

Pharmacologic Study

Factors Involved in the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies

The Journal of Clinical Pharmacology ◽

10.1177/0091270003256675 ◽

2003 ◽

Vol 43 (10) ◽

pp. 1124-1135 ◽

Cited By ~ 10

Author(s):

Michelle A. Rudek ◽

Jürgen Venitz ◽

Yuichi Ando ◽

Eddie Reed ◽

James M. Pluda ◽

...

Keyword(s):

Metastatic Cancer ◽

Experimental Studies ◽

Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study

Journal of Clinical Oncology ◽

10.1200/jco.20.1.153 ◽

2002 ◽

Vol 20 (1) ◽

pp. 153-159 ◽

Cited By ~ 59

Author(s):

M. Cianfrocca

Keyword(s):

Phase I ◽

Kaposi's Sarcoma ◽

Kaposi’S Sarcoma ◽

A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours

Annals of Oncology ◽

10.1023/a:1008347630465 ◽

2000 ◽

Vol 11 (12) ◽

pp. 1579-1584 ◽

Cited By ~ 22

Author(s):

H. Hirte ◽

R. Goel ◽

P. Major ◽

L. Seymour ◽

S. Huan ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Solid Tumours ◽

Dose Escalation Study ◽

The Matrix

PI-51Population pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer

Clinical Pharmacology & Therapeutics ◽

10.1016/j.clpt.2005.12.072 ◽

2006 ◽

Vol 79 (2) ◽

pp. P20-P20 ◽

Cited By ~ 1

Author(s):

J LI ◽

M RUDEK ◽

J VENITZ ◽

E REED ◽

W FIGG ◽

...

Keyword(s):

Metastatic Cancer ◽

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s002800100330 ◽

2001 ◽

Vol 48 (4) ◽

pp. 269-274 ◽

Cited By ~ 29

Author(s):

Elisabeth Heath ◽

Seamus O'Reilly ◽

Rachel Humphrey ◽

Pavur Sundaresan ◽

Ross Donehower ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Trial ◽

Advanced Solid Tumors ◽

The Matrix